drugset / Trial / NCT02247726

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

NCT02247726

Phase 2 Completed 50 enrolled Novavax
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of an RSV-F protein nanoparticle vaccine, with aluminum, in healthy third-trimester pregnant women and to assess the impact of maternal immunization on infant safety through one year of life.

Timeline

Start
2014-09
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject RSV F vaccine Vaccine 0.5 ml Other